Form 4: Verve Therapeutics Director's Stock Options Converted in Eli Lilly Merger

Verve Therapeutics director Alexander Cumbo's stock options were cancelled and converted to cash and contingent value rights following the merger with Eli Lilly and Company.

Summary

• Alexander Cumbo, a Director of Verve Therapeutics, Inc., reported the cancellation of his stock options.
• The cancellation occurred due to an Agreement and Plan of Merger, dated June 16, 2025, between Verve Therapeutics, Inc., Eli Lilly and Company, and Ridgeway Acquisition Corporation.
• At the effective time of the merger, all outstanding stock options with an exercise price less than $10.50 per share were automatically cancelled.
• Holders of these "Cash-Out Stock Options" received cash equal to the difference between the $10.50 Cash Consideration and the option's exercise price, multiplied by the total number of shares underlying the option.
• Additionally, holders received one non-tradeable contingent value right (CVR) for each share subject to the cancelled option.
• Mr. Cumbo's options included 136,139 shares at an exercise price of $5.02 and 42,200 shares at an exercise price of $5.73.
• Following the transaction, Mr. Cumbo beneficially owns 0 shares related to these options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a disclosure of a past event, the director received cash for in-the-money options and CVRs, which is a positive outcome for the option holder. However, it's not a direct indicator of the company's ongoing performance or future prospects, as the company is being acquired.

Positives

• Director Alexander Cumbo received cash consideration for his stock options, reflecting the difference between the merger price of $10.50 per share and his lower exercise prices ($5.02 and $5.73).
• The receipt of non-tradeable contingent value rights (CVRs) provides potential future value based on specific milestones related to the acquired assets.

Negatives

• The stock options were cancelled, meaning the director no longer holds direct equity options in Verve Therapeutics.
• The contingent value rights are non-tradeable, limiting liquidity for that portion of the consideration.

Risks

• The contingent value rights received are non-tradeable, which limits their liquidity and immediate value realization.

Future Outlook

This Form 4 filing details a past transaction related to a merger and does not provide forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

This filing reflects the finalization of a significant corporate transaction, the acquisition of Verve Therapeutics by Eli Lilly and Company. Such mergers are common in the biotechnology and pharmaceutical sectors, driven by strategic portfolio expansion, access to innovative pipelines, or consolidation. The structure of the deal, including cash consideration and contingent value rights, is a typical mechanism used in biotech acquisitions to manage risk and incentivize future performance based on clinical or regulatory milestones.

Comparison to Industry Standards

• This filing reports a standard transaction resulting from a corporate merger, where outstanding equity awards are typically converted or cancelled according to the merger agreement.
• The use of contingent value rights (CVRs) in biotech acquisitions, as seen here, is a common industry practice, exemplified by deals such as Bristol Myers Squibb's acquisition of MyoKardia or Sanofi's acquisition of Principia Biopharma, where CVRs were used to tie additional payments to the achievement of specific clinical or regulatory milestones.
• The cash consideration of $10.50 per share for options with lower exercise prices is a standard payout mechanism in such transactions.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• This filing details a transaction involving a director, which is a related party, but it is a standard consequence of a corporate merger and not a new, independent related party transaction.

Stakeholder Impact

• Shareholders: The merger and subsequent option cancellation impact shareholders by finalizing the acquisition terms, converting their equity into cash and CVRs (if applicable to common stock holders, though this filing is specific to options).
• Employees (Option Holders): Employees holding similar stock options would experience the same conversion to cash and CVRs, providing liquidity for their vested options and potential future value from CVRs.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the completion of the merger, which triggered the option cancellation.

Key Dates

Keywords

Verve Therapeutics, VERV, Eli Lilly, Merger, Acquisition, Stock Options, Form 4, Director, Alexander Cumbo, Contingent Value Rights, CVR, Equity Compensation, SEC Filing